1887

Abstract

A novel lateral-flow device (LFD) has been invented for use as a diagnostic tool for invasive aspergillosis (IA). We conducted a meta-analysis to assess the diagnostic accuracy of the device. Published studies that used the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria and provided sufficient data were included. Two reviewers independently collected the data from each study and assessed the risk bias using the Quality Assessment of Diagnostic Accuracy Studies-2. The pooled sensitivity, specificity and diagnostic odds ratio (DOR) were computed and reported with a 95  % confidence interval (CI). Seven studies published between 2008 and March 2015 were included. The pooled sensitivity, specificity and DOR for the proven/probable versus no IA cases were 0.86 (95  % CI, 0.76–0.93), 0.93 (95  % CI, 0.89–0.96) and 65.94 (95  % CI, 27.21–159.81) in the LFD test using bronchoalveolar lavage (BAL) fluid, and 0.68 (95  % CI, 0.52–0.81), 0.87 (95  % CI, 0.80–0.92) and 11.90 (95  % CI, 3.54–39.96) in the LFD test using serum. We concluded that the LFD had a good diagnostic value in immunocompromised patients at risk of IA. The BAL LFD might have a better performance than the serum LFD test.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000092
2015-07-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/64/7/702.html?itemId=/content/journal/jmm/10.1099/jmm.0.000092&mimeType=html&fmt=ahah

References

  1. Ascioglu S., Rex J.H., de Pauw B., Bennett J.E., Bille J., Crokaert F., Denning D.W., Donnelly J.P., Edwards J.E., other authors. 2002; Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14 [View Article]
    [Google Scholar]
  2. Azoulay E., Dupont H., Tabah A., Lortholary O., Stahl J.P., Francais A., Martin C., Guidet B., Timsit J.F. 2012; Systemic antifungal therapy in critically ill patients without invasive fungal infection. Crit Care Med 40:813–822 [View Article]
    [Google Scholar]
  3. Cochran W.G. 1954; The combination of estimates from different experiments. Biometrics 10:101–129 [View Article]
    [Google Scholar]
  4. Cornillet A., Camus C., Nimubona S., Gandemer V., Tattevin P., Belleguic C., Chevrier S., Meunier C., Lebert C., other authors. 2006; Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 43:577–584 [View Article]
    [Google Scholar]
  5. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., Pappas P.G., Maertens J., Lortholary O., other authors. 2008; Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821 [View Article]
    [Google Scholar]
  6. Guinea J., Bouza E. 2014; Current challenges in the microbiological diagnosis of invasive aspergillosis. Mycopathologia 178:403–416 [View Article]
    [Google Scholar]
  7. Held J., Schmidt T., Thornton C.R., Kotter E., Bertz H. 2013; Comparison of a novel Aspergillus lateral-flow device and the Platelia® galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. Infection 41:1163–1169 [View Article]
    [Google Scholar]
  8. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. 2003; Measuring inconsistency in meta-analyses. Brit Med J 327:557–560 [View Article]
    [Google Scholar]
  9. Hoenigl M., Koidl C., Duettmann W., Seeber K., Wagner J., Buzina W., Wölfler A., Raggam R.B., Thornton C.R., Krause R. 2012; Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J Infect 65:588–591 [View Article]
    [Google Scholar]
  10. Hoenigl M., Prattes J., Spiess B., Wagner J., Prueller F., Raggam R.B., Posch V., Duettmann W., Hoenigl K., other authors. 2014; Performance of galactomannan, β-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 52:2039–2045 [View Article]
    [Google Scholar]
  11. Johnson G., Ferrini A., Dolan S.K., Nolan T., Agrawal S., Doyle S., Bustin S.A. 2014; Biomarkers for invasive aspergillosis: the challenges continue. Biomarkers Med 8:429–451 [View Article]
    [Google Scholar]
  12. Kontoyiannis D.P., Marr K.A., Park B.J., Alexander B.D., Anaissie E.J., Walsh T.J., Ito J., Andes D.R., Baddley J.W., other authors. 2010; Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis 50:1091–1100 [View Article]
    [Google Scholar]
  13. Leeflang M.M., Debets-Ossenkopp Y.J., Visser C.E., Scholten R.J., Hooft L., Bijlmer H.A., Reitsma J.B., Bossuyt P.M., Vandenbroucke-Grauls C.M. 2008; Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev2008CD007394 Medline
    [Google Scholar]
  14. Marr K.A., Laverdiere M., Gugel A., Leisenring W. 2005; Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40:1762–1769 [View Article]
    [Google Scholar]
  15. Mengoli C., Cruciani M., Barnes R.A., Loeffler J., Donnelly J.P. 2009; Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 9:89–96 [View Article]
    [Google Scholar]
  16. Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., Pfaller M., Chang C., Webster K., Marr K. 2009; Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 48:265–273 [View Article]
    [Google Scholar]
  17. Onishi A., Sugiyama D., Kogata Y., Saegusa J., Sugimoto T., Kawano S., Morinobu A., Nishimura K., Kumagai S. 2012; Diagnostic accuracy of serum 1,3-β-d-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 50:7–15 [View Article]
    [Google Scholar]
  18. Pagano L., Caira M., Candoni A., Offidani M., Martino B., Specchia G., Pastore D., Stanzani M., Cattaneo C., other authors. 2010; Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 Registry Study. Haematologica 95:644–650 [View Article]
    [Google Scholar]
  19. Prattes J., Flick H., Prüller F., Koidl C., Raggam R.B., Palfner M., Eigl S., Buzina W., Zollner-Schwetz I., other authors. 2014; Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases. Am J Respir Crit Care Med 190:922–929 [View Article]
    [Google Scholar]
  20. Thornton C.R. 2008; Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol 15:1095–1105 [View Article]
    [Google Scholar]
  21. Thornton C.R. 2010; Detection of invasive aspergillosis. Adv Appl Microbiol 70:187–216 [CrossRef]
    [Google Scholar]
  22. Thornton C., Johnson G., Agrawal S. 2012; Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. J Vis Exp20123721 Medline
    [Google Scholar]
  23. van der Linden J.W., Snelders E., Kampinga G.A., Rijnders B.J., Mattsson E., Debets-Ossenkopp Y.J., Kuijper E.J., Van Tiel F.H., Melchers W.J., Verweij P.E. 2011; Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007–2009. Emerg Infect Dis 17:1846–1854 [View Article]
    [Google Scholar]
  24. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., Morrison V.A., Segal B.H., Steinbach W.J., other authors. 2008; Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360 [View Article]
    [Google Scholar]
  25. White P.L., Parr C., Thornton C., Barnes R.A. 2013; Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol 51:1510–1516 [View Article]
    [Google Scholar]
  26. Whiting P.F., Rutjes A.W., Westwood M.E., Mallett S., Deeks J.J., Reitsma J.B., Leeflang M.M., Sterne J.A., Bossuyt P.M., QUADAS-2 Group. 2011; QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536 [View Article]
    [Google Scholar]
  27. Wiederhold N.P., Najvar L.K., Bocanegra R., Kirkpatrick W.R., Patterson T.F., Thornton C.R. 2013; Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis. J Clin Microbiol 51:459–465 [View Article]
    [Google Scholar]
  28. Willinger B., Lackner M., Lass-Flörl C., Prattes J., Posch V., Selitsch B., Eschertzhuber S., Hönigl K., Koidl C., other authors. 2014; Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis in solid organ transplant patients: a semiprospective multicenter study. Transplantation 98:898–902 [View Article]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000092
Loading
/content/journal/jmm/10.1099/jmm.0.000092
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error